Sio Capital Management LLC Boosts Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Sio Capital Management LLC lifted its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 18.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,214,239 shares of the company's stock after buying an additional 505,831 shares during the period. PMV Pharmaceuticals comprises 1.9% of Sio Capital Management LLC's holdings, making the stock its 17th largest holding. Sio Capital Management LLC owned approximately 6.21% of PMV Pharmaceuticals worth $4,789,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Public Employees Retirement System of Ohio increased its stake in PMV Pharmaceuticals by 174.2% during the first quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company's stock worth $39,000 after acquiring an additional 14,457 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in PMV Pharmaceuticals by 71.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company's stock worth $73,000 after buying an additional 17,858 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in PMV Pharmaceuticals during the second quarter valued at $101,000. Evoke Wealth LLC purchased a new stake in shares of PMV Pharmaceuticals in the second quarter valued at $102,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of PMV Pharmaceuticals by 570.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company's stock worth $113,000 after acquiring an additional 59,452 shares during the last quarter. 90.20% of the stock is currently owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ:PMVP traded up $0.02 during trading on Friday, reaching $1.62. The stock had a trading volume of 81,924 shares, compared to its average volume of 395,337. The company has a market capitalization of $83.84 million, a P/E ratio of -1.60 and a beta of 1.49. The firm's 50-day simple moving average is $1.58 and its 200 day simple moving average is $1.63. PMV Pharmaceuticals, Inc. has a one year low of $1.40 and a one year high of $3.47.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). Equities research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PMVP has been the topic of a number of recent analyst reports. Oppenheimer raised shares of PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 price objective on the stock in a research report on Friday, November 8th. HC Wainwright restated a "buy" rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $5.80.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.